2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim S, Nurieva R, Lazar A, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks J, Awiwi M, Elsayes K, Soto L, Melendez B, Davies M, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison J, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022, 40: 509-523.e6. PMID: 35537412, PMCID: PMC9221568, DOI: 10.1016/j.ccell.2022.04.004.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeExperimental autoimmune encephalomyelitisInterleukin-6 blockadeInterleukin-6Anti-cytotoxic T-lymphocyte-associated antigen 4T-lymphocyte-associated antigen 4Anti-programmed death-1Experimental autoimmune encephalomyelitis symptomsImmune-related adverse eventsICB-treated patientsPromote tumor immunityAnti-CTLA-4Anti-PD-1Improve tumor controlEffector T cellsT helper 1T helper 17Expression of interleukin-6Chemotactic markersImmunotherapy toxicityReduced Th17Antitumor immunityCheckpoint blockadeTumor controlDeath-1
2020
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors
Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020, 85: 106628. PMID: 32474388, DOI: 10.1016/j.intimp.2020.106628.Peer-Reviewed Original ResearchConceptsImmune-related adverse effectsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsCancer patientsPredictive biomarkersTumor respondersAnti-PD-1/PD-L1 immunotherapyCell death protein 1 (PD-1) pathwayT-lymphocyte-associated antigen 4PD-L1 immunotherapyVariety of malignanciesAdvanced human cancersConventional anticancer therapiesDegree of severityProtein 1 pathwayNew potential mechanismAntigen-4Cancer immunotherapyToxicity profileImmunotherapyTherapyPatientsAdverse effectsAnticancer therapyUnderstanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review
Lee K, Ahn B, Cha D, Jang W, Choi E, Park S, Park J, Oh J, Jung D, Park H, Park J, Suh Y, Jin D, Lee S, Jang Y, Yoon T, Park M, Seong Y, Pyo J, Yang S, Kwon Y, Jung H, Lim C, Hong J, Park Y, Choi E, Shin J, Kronbichler A. Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review. Autoimmunity Reviews 2020, 19: 102469. PMID: 31918027, DOI: 10.1016/j.autrev.2020.102469.Peer-Reviewed Original ResearchConceptsImmunopathogenesis of autoimmune diseasesSystemic lupus erythematosusAutoimmune diseasesShort interfering ribonucleic acidTumor necrosis factorInflammatory bowel diseaseCytotoxic T-lymphocyte-associated antigen 4T-lymphocyte-associated antigen 4Rheumatoid arthritisTreatment of autoimmune disordersMultiple sclerosisPathogenic inflammatory responsesMolecular basis of autoimmune diseasesMechanisms of autoimmune diseasesAnti-inflammatory cytokinesLevels of interleukinsInadequate immune activationCTLA-4Antigen 4Cytokine antagonistsInvestigate cytokine regulationInterferon-gLupus erythematosusAutoimmune disordersGene modules
2018
Anti‐PD‐1 Therapy‐Associated Perforating Colitis
Celli R, Kluger HM, Zhang X. Anti‐PD‐1 Therapy‐Associated Perforating Colitis. Case Reports In Gastrointestinal Medicine 2018, 2018: 3406437. PMID: 29955400, PMCID: PMC6000840, DOI: 10.1155/2018/3406437.Peer-Reviewed Original ResearchAnti-PD-1/PD-L1PD-L1T-lymphocyte-associated antigen 4Immune-related adverse effectsCell death protein 1PD-1 inhibitorsDeath protein 1T-cell regulatory moleculesAdvanced malignanciesColonic perforationAntigen-4Metastatic melanomaTimely diagnosisColitisAdverse effectsProtein 1PerforationCell regulatory moleculesRegulatory moleculesPembrolizumabDiarrheaPatientsMalignancyMelanomaDiagnosis
2014
Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research 2014, 20: 3310-3318. PMID: 24721645, DOI: 10.1158/1078-0432.ccr-13-2906.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansMaleMelanomaMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPrognosisProspective StudiesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateYoung AdultConceptsInterleukin-1 receptor-associated kinase 3Cytotoxic T-lymphocyte-associated antigen 4Federal Drug AdministrationT-lymphocyte-associated antigen 4Multicenter phase II studyPretreatment peripheral blood samplesMulticenter phase III studyThioredoxin reductase 1Four-gene modelCathepsin DCTLA-4 blockadePhase II studyPhase III studyTreatment-naïve patientsSubset of patientsPeripheral blood samplesReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionU.S. Federal Drug AdministrationExpression levelsPrior therapyII studyIII studyClinical predictorsPatient subsets
2013
Ipilimumab-induced Perforating Colitis
Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced Perforating Colitis. Journal Of Clinical Gastroenterology 2013, 47: 781-785. PMID: 23632354, PMCID: PMC6091636, DOI: 10.1097/mcg.0b013e31828f1d51.Peer-Reviewed Original ResearchConceptsIpilimumab-induced colitisSteroid therapyHistologic findingsT-lymphocyte-associated antigen 4Common side effectsAssociated histologic findingsBowel perforationSubtotal colectomyMucosal biopsiesSegmental resectionStandard treatmentAntigen-4Metastatic melanomaColitisSide effectsMonoclonal antibodiesTherapyIpilimumabColectomyDiarrheaPatientsPerforationTreatmentResectionBiopsy
2004
An Autoimmune Disease-Associated CTLA-4 Splice Variant Lacking the B7 Binding Domain Signals Negatively in T Cells
Vijayakrishnan L, Slavik JM, Illés Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, Wicker LS, Kuchroo VK. An Autoimmune Disease-Associated CTLA-4 Splice Variant Lacking the B7 Binding Domain Signals Negatively in T Cells. Immunity 2004, 20: 563-575. PMID: 15142525, DOI: 10.1016/s1074-7613(04)00110-4.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntigens, CDAntigens, DifferentiationAutoimmune DiseasesB7-1 AntigenBlotting, WesternCloning, MolecularCTLA-4 AntigenFemaleFlow CytometryHumansMembrane ProteinsMiceMice, Inbred NODMolecular Sequence DataReceptors, Antigen, T-CellReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSignal TransductionT-LymphocytesConceptsCytotoxic T-lymphocyte-associated antigen 4T cell responsesT cellsNOD miceAutoimmune diseasesT cell-mediated autoimmune diseaseT-lymphocyte-associated antigen 4Cell responsesCell-mediated autoimmune diseaseSusceptible NOD miceRegulatory T cellsNOD congenic miceCTLA-4 locusAntigen-4B7-1B7-2Primary T cellsCongenic miceSplice variantsMiceNegative signalingMYPPPY motifDiseaseType IGenetic linkage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply